Dutch biotech company Pepscope, offering endogenous protein kinase activity profiling technologies, has secured €4.3 million funding to further develop and commercialize their lead product QuantaKinome.
Switzerland-based RetinAI Medical will collaborate with Novartis Pharma in a multi-year agreement which will see RetinAI’s artificial intelligence tools employed to support multiple projects in ophthalmology. Both companies have previously worked successfully on pilot projects in this disease area.
SYNLAB, the leading medical diagnostic services provider in Europe, has agreed to sell its Analytics & Services (A&S) unit to SGS, the world’s leading inspection, verification, testing and certification company. The proceeds of the sale will remain in the group for future use.
Fluorescence microscopy is widely used in biochemistry and life sciences because it allows scientists to directly observe cells and certain compounds in and around them. Fluorescent molecules absorb light within a specific wavelength range and then re-emit it at the longer wavelength range. However, the major limitation of conventional fluorescence microscopy techniques is that the […]
A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat Covid-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings.
Dr. Michael Teitell is director of the UCLA Jonsson Comprehensive Cancer Center. Scientists from the UCLA Jonsson Comprehensive Cancer Center have developed a simple, high-throughput method for transferring isolated mitochondria and their associated mitochondrial DNA into mammalian cells. This approach enables researchers to tailor a key genetic component of cells, to study and potentially treat […]
One of the physiopathological characteristics of COVID-19 that has most baffled the scientific and medical community is what is known as “silent hypoxemia” or “happy hypoxia”. Patients suffering this phenomenon, the causes of which are still unknown, have severe pneumonia with markedly decreased arterial blood oxygen levels (known as hypoxemia). However, they do not report […]
A new synthetic probe offers a safe and straightforward approach for visualizing chromosome tips in living cells. The probe was designed by scientists at the Institute for Integrated Cell-Material Science (iCeMS) and colleagues at Kyoto University, and could advance research into aging and a wide range of diseases, including cancers.
ZTA Biotech, a Budapest-based biotech startup has announced the breakthrough development of a COVID-19 antibody (IgG) test using the ELISA protocol. This new detection method represents a great step forward in determining if patients have had COVID-19 and if they might still have immunity to the disease. Early results have proven 100% in specificity after testing 280 samples, and 100% sensitivity by testing 260 samples of recovered and symptomatic patients.
One of the conundrums presented by COVID-19 is that it is not uncommon for patients to present with remarkably low oxygen saturation levels but with very little breathlessness. Additionally, it has been noted that there is an additional risk of stroke in COVID-19 patients (and COVID-19-recovered patients) and that they seem to have what is being referred to as ‘sticky blood’. A recent paper by Professor Yost (Department of Pediatrics, University of Utah School of Medicine, UT, USA) and colleagues ‘Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome’ discusses the role that neutrophil extracellular traps (NETs) can play in the development of these symptoms and prothrombotic disease outcomes. CLI was very fortunate to catch up with Professor Yost to learn more about NETs and their effects in COVID-19 and other conditions.
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.